Crafting targeted peptide-based therapies in specialist therapeutic areas
ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France
Our research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.
This research, for original biopolymer-based active compounds, has led us to collaborate with the world-renowned Centre National de la Recherche Scientifique, (CNRS) in France and Imperial College London. These collaborations enable us to access innovative research with substantial embedded value and to work with many leading scientists and clinicians.
ImmuPharma has exclusive rights to all of its intellectual property assets. Since a major Board and management restructuring, the team has refocused its key pipeline portfolio to maximise long-term shareholder value.
Our pipeline
Our pipeline of cutting-edge peptide-based therapies is focussed on two pivotal therapeutic areas: Autoimmunity & Inflammation and Anti-infection.
Autoimmunity & Inflammation
Thanks to its unique mechanism of action, P140 has a very high potential for achieving several therapeutic repositionings in the complex field of autoimmune diseases. This potential isn’t just theoretical; it has been borne out in various in-vivo models, yielding results that inspire optimism.
- P140 (Lupuzor™) for Systemic Lupus Erythematosus (SLE) (Phase 3 / pivotal)
- P140 for CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) (Phase 2/3 adaptive/pivotal)
Anti-infection
Leveraging our unique technology based on reprogramming ADMET properties of compounds which have poor availabilities, we’ve engineered anti-infective agents that marry ease of administration with heightened efficacy and safety.
- BioAMB, a groundbreaking amphotericin-B variant that promises both efficiency and safety (preclinical)
- BioCIN, an innovative vancomycin based treatment for efficient, safe anti-infection treatment (preclinical)
Business development
Our commercial strategy is to out-license our assets in development at value inflection points, to leading international corporations that are well-placed to further develop and/or commercialise our drugs.
ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement for P140 in the US.
Why Invest in ImmuPharma?
- A rich portfolio with 2 highly attractive late-stage clinical indications – SLE & CIDP
- Near-term business development opportunities across all programs
- Innovative P140 Bio-drug platform has the potential in several autoimmune diseases and life cycle management through it’s second generation P140
The story so far...
2006
Successful listing on AIM of the London Stock Exchange
To fund the development of its lead drug candidate, Lupuzor™ through Phase 1/2 development
2008
Option agreement signed with US Cephalon Inc., for LupuzorTM
Initial US$15m upfront payment in advance to Phase 2b data being announced
2009
Positive Phase 2b results announced for LupuzorTM
• LupuzorTM successfully licensed to Cephalon
• ImmuPharma receives a further upfront payment of US$30 million from Cephalon
• US$500 million cash milestone payment structure plus high royalties on future sales
• Largest deal in Europe that year
2011
ImmuPharma regained all product rights back for LupuzorTM & P140 platform
Following the acquisition of Cephalon by Teva Pharmaceuticals
2016
A pivotal Phase 3 international study commences for LupuzorTM in lupus patients
In sites across Europe, Mauritius and USA
SPA and Fastrack designation granted by FDA
2018
Lupuzor Phase 3 trial results demonstrated a superior response rate over placebo in primary analysis
Due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial’s primary end point was not met
2019
ImmuPharma successfully signs exclusive licence & development agreement for LupuzorTM, with US Avion Pharmaceuticals
Avion to fund new international Phase 3 trial for LupuzorTM and commercialise in the US
Avion have rights to explore clinical development for other auto-immune indications within US
2020
A new Phase 3 clinical trial design for Lupuzor™ agreed and submitted to FDA
Trial design to select the most responsive lupus patients by biomarker profile
2021
FDA agrees new optimised Phase 3 trial design
FDA requests Phase 1 PK study to assess presence of Lupuzor™ in blood after single administration
Successful Board and management team restructuring completed
Bordeaux R&D team established
Pipeline refocused on two key therapeutic areas:
- Autoimmunity & Inflammation (Lupuzor™/P140)
- Anti-infectives (BioAMB & BioCIN)
2022
MHRA approves commencement of the PK Phase I study
- Dosing commencing in February 2022
- Study results to be available around the end of Q1 2022
- Successful completion of PK study
- Ongoing discussions with FDA regarding clinical programme of Lupuzor™
2023
Portfolio in two core therapy areas with 4 key assets:
Autoimmunity & Inflammation
- Lupuzor™ (P140) for Lupus (Ph 3 pivotal)
- Simbec-Orion appointed as CRO for Ph3 Lupuzor™ study
- P140 for CIDP (Ph2/3 adaptive/pivotal)
Anti-infectives
- BioAMB, a novel, improved amphotericin-B (Late preclinical)
- BioCIN, a novel, improved vancomycin (Early preclinical)
2024
Continuing progress of P140 platform, key assets and business development
- Realisation of £1.5m from sale of Incanthera shares
- New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform
- Attendance at Bio-Europe Spring 2024 | 18-20 March 2024, Barcelona
2025
The start of a transformational year
- Significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology platform
- Oversubscribed £2.91 fundraising
- Breakthrough findings into autoimmune disease
- Representation at JP Morgan and Biotech Showcase Healthcare Conferences